Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Tax Provisions (2019 - 2025)

Historic Tax Provisions for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Q3 2025 value amounting to $18.3 million.

  • Catalyst Pharmaceuticals' Tax Provisions rose 3701.67% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.7 million, marking a year-over-year increase of 1877.96%. This contributed to the annual value of $52.9 million for FY2024, which is 5118.23% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Tax Provisions of $18.3 million as of Q3 2025, which was up 3701.67% from $17.2 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Tax Provisions high stood at $23.7 million for Q4 2023, and its period low was -$7.3 million during Q3 2023.
  • In the last 5 years, Catalyst Pharmaceuticals' Tax Provisions had a median value of $7.5 million in 2022 and averaged $9.1 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first skyrocketed by 50668.84% in 2021, then tumbled by 32267.57% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Tax Provisions (Quarter) stood at $3.5 million in 2021, then skyrocketed by 115.1% to $7.5 million in 2022, then soared by 214.94% to $23.7 million in 2023, then decreased by 21.02% to $18.7 million in 2024, then fell by 2.64% to $18.3 million in 2025.
  • Its Tax Provisions stands at $18.3 million for Q3 2025, versus $17.2 million for Q2 2025 and $14.5 million for Q1 2025.